uracil has been researched along with Renal Insufficiency in 9 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine and compare the ratio of uracil (U) to dihydrouracil (UH(2)) concentrations in plasma as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency." | 7.78 | Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency. ( Edwards, GL; Freeman, KG; Saba, CF; Schmiedt, CW, 2012) |
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 5.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| "Ombitasvir, paritaprevir (given with low-dose ritonavir), and dasabuvir are direct-acting antivirals (DAAs) used with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) infection." | 4.95 | Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. ( Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR, 2017) |
| "To determine and compare the ratio of uracil (U) to dihydrouracil (UH(2)) concentrations in plasma as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency." | 3.78 | Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency. ( Edwards, GL; Freeman, KG; Saba, CF; Schmiedt, CW, 2012) |
| " In the double-blind phase, the incidence of treatment-emergent adverse events (TEAEs) was 72." | 2.94 | Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study. ( Achira, M; Ishida, K; Kaku, K; Shimizu, K; Umeda, Y, 2020) |
| " We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT." | 2.73 | Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. ( Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007) |
| " Four of the five commercially available DPP-4 inhibitors are subject to significant renal clearance, and pharmacokinetic studies in people with renal impairment have led to lower recommended doses based on creatinine clearance in order to prevent drug accumulation." | 2.50 | Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. ( Davis, TM, 2014) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| "This study aimed to build a mathematical model of physiologically based pharmacokinetic combined DPP-4 occupancy (PBPK-DO) in humans to provide some recommendations for dosing adjustment in patients with renal impairment." | 1.72 | Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling. ( Li, B; Liu, H; Liu, Y; Ren, C; Wang, G; Wu, C; Yu, S; Zhang, J, 2022) |
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 1.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| "Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU)." | 1.32 | A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). ( Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Carriat, L | 1 |
| Quaranta, S | 1 |
| Solas, C | 1 |
| Rony, M | 1 |
| Ciccolini, J | 1 |
| Wu, C | 1 |
| Liu, H | 1 |
| Yu, S | 1 |
| Ren, C | 1 |
| Zhang, J | 1 |
| Wang, G | 1 |
| Li, B | 1 |
| Liu, Y | 1 |
| Sperl, J | 1 |
| Kreidlova, M | 1 |
| Merta, D | 1 |
| Chmelova, K | 1 |
| Senkerikova, R | 1 |
| Frankova, S | 1 |
| Kaku, K | 1 |
| Ishida, K | 1 |
| Shimizu, K | 1 |
| Achira, M | 1 |
| Umeda, Y | 1 |
| Davis, TM | 1 |
| Polepally, AR | 1 |
| Badri, PS | 1 |
| Eckert, D | 1 |
| Mensing, S | 1 |
| Menon, RM | 1 |
| Schmiedt, CW | 1 |
| Saba, CF | 1 |
| Freeman, KG | 1 |
| Edwards, GL | 1 |
| O'Donnell, A | 1 |
| Punt, CJ | 1 |
| Judson, I | 1 |
| Van Maanen, L | 1 |
| Suttle, AB | 1 |
| Ertel, P | 1 |
| Beale, P | 1 |
| Inoue, S | 1 |
| Ohtani, H | 1 |
| Tsujimoto, M | 1 |
| Hori, S | 1 |
| Sawada, Y | 1 |
2 reviews available for uracil and Renal Insufficiency
| Article | Year |
|---|---|
Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV I | 2014 |
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Area Under Curve; Carbamates; | 2017 |
2 trials available for uracil and Renal Insufficiency
| Article | Year |
|---|---|
Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Diet Therapy; Dipeptidyl-Peptidase IV Inhibitors; Dou | 2020 |
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother | 2007 |
5 other studies available for uracil and Renal Insufficiency
| Article | Year |
|---|---|
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.
Topics: Computer Simulation; Heterocyclic Compounds, 2-Ring; Humans; Models, Biological; Pyrans; Renal Insuf | 2022 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Topics: 2-Naphthylamine; Anilides; Antihypertensive Agents; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2018 |
Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.
Topics: Animals; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (NADP); Dog Diseases; Dog | 2012 |
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Therapy, Combination; Enzym | 2003 |